Patrick J McEnany, Board Member at Catalyst Pharmaceuticals CPRX, reported an insider sell on November 13, according to a new SEC filing. Tracking the Thursday's morning session, Catalyst ...

Catalyst Pharmaceuticals Inc (CPRX) reports a 25.3% increase in total revenue and updates its full-year guidance, while ...

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse ...

Truist Financial analyst Joon Lee reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

We are honored to be recognized by BioSpace as one of the Best Places to Work in 2025,” said Richard J. Daly, President and Chief Executive Officer. “Our goal has always been to create an environment ...

For the quarter ended September 2024, Catalyst Pharmaceutical (CPRX) reported revenue of $128.7 million, up 25.3% over the same period last year. EPS came in at $0.57, compared to -$0.24 in the ...

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...